Bookmark and Share

CEO Linda Grais, Ocera Therapeutics, Inc. Insider Buys $59,300 of Shares on July, 11 2014

Linda Grais, CEO of Ocera Therapeutics, Inc., bought 10,000 shares of Ocera Therapeutics, Inc. (Stock Symbol: Enter OCRX) at $5.93 per share for a total amount of $59.3 thousand on July, 11 2014.

Ocera Therapeutics, Inc. is located in Palo Alto, CA.

On 07/10/2014, Ocera Therapeutics, Inc. announced that it has priced an underwritten public offering of 4,200,000 shares of its common stock at an offering price of $6.00 per share. The offering will raise gross proceeds to Ocera of $25.2 million before deducting the underwriting discount and other offering expenses. Ocera has also granted the underwriters a 30-day option to purchase up to an additional 630,000 shares of common stock, which would result in additional gross proceeds of $3.78 million, if exercised in full.

On 05/06/2014, Ocera Therapeutics, Inc. announced its latest quarterly results. Ocera Therapeutics, Inc. (Nasdaq:OCRX), a biopharmaceutical company focused on innovative therapeutics for orphan liver disease, announced today its financial results for the first quarter ended March 31, 2014. Net loss for the period was $4.1 million, including net loss from continuing operations of $5.2 million offset by a $1.1 million net income from discontinued operations, compared to a net loss of $0.7 million in the same period of 2013. As of March 31, 2013, Ocera had cash, cash equivalents and investments of $43.1 million.

According to Capital IQ, Ocera Therapeutics, Inc. has a market cap of $87.96 million, an enterprise value of $44.37 million.

Ocera Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the development and commercialization of OCR-002, which is in Phase IIb trials for the treatment of hepatic encephalopathy in patients with liver cirrhosis, acute liver injury, and acute liver failure, as well as in the areas of unmet medical need. The company was founded in 2004 and is headquartered in Palo Alto, California.

Linda Grais’s most recent annual compensation from Ocera Therapeutics, Inc. is a salary of $198,802, $5,642,870 in other compensation, and a total compensation of $5,841,680. Mrs. Grais is 57 years old.

According to her biography, is President, Chief Executive Officer, Director of Ocera Therapeutics, Inc. Prior to her employment by Private Ocera, Dr. Grais served as a Managing Member at InterWest Partners, a venture capital firm from May 2005 until February 2011. From July 1998 to July 2003, Dr. Grais was a founder and executive vice president of SGX Pharmaceuticals Inc., a drug discovery company focusing on new treatments for cancer. Prior to that, she was a corporate attorney at Wilson Sonsini Goodrich & Rosati, where she practiced in such areas as venture financings, public offerings and strategic partnerships. Before practicing law, Dr. Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco. Dr. Grais received a B.A. from Yale University, magna cum laude, and Phi Beta Kappa, an M.D. from Yale Medical School and a J.D. from Stanford Law School. As of President and Chief Executive Officer, Dr. Grais brings to our Board of Directors her diverse training and experience as both a medical doctor and a lawyer, her experience as a founder and senior executive of a pharmaceutical company, and her experience as an investor in new life sciences companies. She currently serves on the board of directors of Arca Biopharma, Inc (NASDAQ:ABIO).

All stories in DailyStocks.com are for informational purposes only. This is NOT a stock recommendation. This DailyStocks.com story is a daily light analysis featuring a stock with insider buying. With some caveats, insiders purchase a stock because they think the stock is going up. There are other factors to consider such as size of the transaction relative to their compensation and net worth. Sometimes, insiders might be propping a stock price up for future financing. Sometimes, the amount of insider buying are misread or misreported. Each month, DailyStocks releases a a summary of the stocks with insider buying. Sign up for the free monthly newsletter at DailyStocks.com .

About Dailystocks.com: DailyStocks.com is the place where you can find stories about stocks with insider buying, where you can educate yourself about stock market investing, and where you can perform the stock search engine analysis – you enter a stock symbol, and you get a resulting page of stock ticker indexed links so that you do not have to type the stock symbol each time.


Leave a Reply

  

  

  

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>


-------------------------------------------------------------------------------------------------------------------------
All stories in DailyStocks.com are for informational purposes only. This is NOT a stock recommendation. This DailyStocks.com story is a daily light analysis featuring a stock with insider buying. With some caveats, insiders purchase a stock because they think the stock is going up. There are other factors to consider such as size of the transaction relative to their compensation and net worth. Sometimes, insiders might be propping a stock price up for future financing. Sometimes, the amount of insider buying are misread or misreported. Each month, DailyStocks releases a a summary of the stocks with insider buying. Sign up for the free monthly newsletter at DailyStocks.com . About Dailystocks.com: DailyStocks.com is the place where you can find stories about stocks with insider buying, where you can educate yourself about stock market investing, and where you can perform the stock search engine analysis – you enter a stock symbol, and you get a resulting page of stock ticker indexed links so that you do not have to type the stock symbol each time.